‘Personalised’ treatment results due next year

[MSUK]

After the Phase 2b clinical trial achieved full enrolment with 190 secondary progress multiple sclerosis (SPMS) patients, Texas-based Opexa Therapeutics is now awaiting results for the company’s lead candidate, Tcelna, which are expected in the second half of 2016..... Read More - http://www.ms-uk.org/tcelna